Skip to content
Homepage
Author:
Immix Biopharma, Inc.
Posted Date:
May 22, 2026
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma, Inc.
May 22, 2026
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
Immix Biopharma, Inc.
May 21, 2026
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
Immix Biopharma, Inc.
May 21, 2026
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
Immix Biopharma, Inc.
April 9, 2026
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones
Immix Biopharma, Inc.
March 30, 2026
Immix Biopharma to Participate in Upcoming Investor Conferences
Immix Biopharma, Inc.
March 3, 2026
Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for NXC-201
Immix Biopharma, Inc.
January 28, 2026
